Terms: = Liver cancer AND AFP, AFPD, FETA, HPAFP AND Clinical Outcome
62 results:
1. Transarterial chemoembolization
Yang B; Yuan M; Yang T; Liao Z; Wu H
Oncol Res; 2022; 30(1):23-33. PubMed ID: 37304009
[TBL] [Abstract] [Full Text] [Related]
2. Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real-world experience.
Lin PT; Hung MH; Shao SC; Chen HY; Chan YY; Chang KC; Lin SM; Ou HT
Cancer Med; 2023 Jul; 12(14):14902-14911. PubMed ID: 37278402
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation and Application of Drug Resistance by Biomarkers in the clinical Treatment of liver cancer.
Huang PS; Wang LY; Wang YW; Tsai MM; Lin TK; Liao CJ; Yeh CT; Lin KH
Cells; 2023 Mar; 12(6):. PubMed ID: 36980210
[TBL] [Abstract] [Full Text] [Related]
4. Accurate prediction of microvascular invasion occurrence and effective prognostic estimation for patients with hepatocellular carcinoma after radical surgical treatment.
Xiong Y; Cao P; Lei X; Tang W; Ding C; Qi S; Chen G
World J Surg Oncol; 2022 Sep; 20(1):328. PubMed ID: 36180867
[TBL] [Abstract] [Full Text] [Related]
5. Deep-learning-based analysis of preoperative MRI predicts microvascular invasion and outcome in hepatocellular carcinoma.
Sun BY; Gu PY; Guan RY; Zhou C; Lu JW; Yang ZF; Pan C; Zhou PY; Zhu YP; Li JR; Wang ZT; Gao SS; Gan W; Yi Y; Luo Y; Qiu SJ
World J Surg Oncol; 2022 Jun; 20(1):189. PubMed ID: 35676669
[TBL] [Abstract] [Full Text] [Related]
6. Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: cancer Metabolism and Immune Status.
Iseda N; Itoh S; Yoshizumi T; Tomiyama T; Morinaga A; Yugawa K; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Kitamura Y; Nagao Y; Toshima T; Harada N; Kohashi K; Baba S; Ishigami K; Oda Y; Mori M
Hepatol Commun; 2022 Apr; 6(4):665-678. PubMed ID: 34687175
[TBL] [Abstract] [Full Text] [Related]
7. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
Hayakawa Y; Tsuchiya K; Kurosaki M; Yasui Y; Kaneko S; Tanaka Y; Ishido S; Inada K; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Izumi N
Invest New Drugs; 2022 Apr; 40(2):392-402. PubMed ID: 34586531
[TBL] [Abstract] [Full Text] [Related]
8. Cyberknife Radiosurgery in Hepatocellular Carcinoma.
Memon B; Kadri S; Sultana N; Saeed K; Ahmed N; Mahmood T
J Coll Physicians Surg Pak; 2021 May; 31(5):532-536. PubMed ID: 34027864
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of the clinical outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
Amioka K; Kawaoka T; Ogawa Y; Kikukawa C; Naruto K; Yoshikawa Y; Ando Y; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Fukuhara T; Mori N; Takaki S; Tsuji K; Masaki K; Honda Y; Kouno H; Kohno H; Chayama K; Aikata H
Oncology; 2021; 99(5):327-335. PubMed ID: 33677453
[TBL] [Abstract] [Full Text] [Related]
10. Circulating tumor cells detected with a microcavity array predict clinical outcome in hepatocellular carcinoma.
Takahashi K; Ofuji K; Hiramatsu K; Nosaka T; Naito T; Matsuda H; Endo K; Higuchi M; Ohtani M; Nemoto T; Nakamoto Y
Cancer Med; 2021 Apr; 10(7):2300-2309. PubMed ID: 33675149
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series.
Wang YF; Dai YH; Lin CS; Chang HC; Shen PC; Yang JF; Hsiang CW; Lo CH; Huang WY
Radiat Oncol; 2021 Jan; 16(1):15. PubMed ID: 33446231
[TBL] [Abstract] [Full Text] [Related]
12. Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype.
Krause J; von Felden J; Casar C; Fründt TW; Galaski J; Schmidt C; Jung C; Ittrich H; Weidemann SA; Krech T; Heumann A; Li J; Fischer L; Sauter G; Lohse AW; Wege H; Schulze K
BMC Cancer; 2020 Nov; 20(1):1130. PubMed ID: 33225916
[TBL] [Abstract] [Full Text] [Related]
13. A Phase II clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.
Changou CA; Shiah HS; Chen LT; Liu S; Luh F; Liu SH; Cheng YC; Yen Y
Oncologist; 2021 Mar; 26(3):e367-e373. PubMed ID: 33140457
[TBL] [Abstract] [Full Text] [Related]
14. Development and Identification of a Nomogram Prognostic Model for Patients with Primary Clear Cell Carcinoma of the liver.
Zhang Z; Xie H; Chen P; Cao P
Med Sci Monit; 2020 Jan; 26():e919789. PubMed ID: 31969554
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic factors for event-free survival in liver transplantation for hepatoblastoma: A single-center experience.
Lauferman L; Halac E; Aredes D; Cañon Reyes I; Cervio G; Dip M; Minetto J; Reijenstein H; Meza V; Gole M; Jacobo Dillon A; Rose A; Imventarza O
Pediatr Transplant; 2019 Dec; 23(8):e13581. PubMed ID: 31531932
[TBL] [Abstract] [Full Text] [Related]
16. Identification of a molecular subtyping system associated with the prognosis of Asian hepatocellular carcinoma patients receiving liver resection.
Ma X; Gu J; Wang K; Zhang X; Bai J; Zhang J; Liu C; Qiu Q; Qu K
Sci Rep; 2019 May; 9(1):7073. PubMed ID: 31068611
[TBL] [Abstract] [Full Text] [Related]
17. Lymphoepithelioma-like hepatocellular carcinoma: A case report and brief review of literature.
Wang JK; Jin YW; Hu HJ; Regmi P; Ma WJ; Yang Q; Liu F; Ran CD; Su F; Zheng EL; Li FY
Medicine (Baltimore); 2017 Dec; 96(51):e9416. PubMed ID: 29390565
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic and therapeutic factors influencing the clinical outcome of hepatoblastoma after liver transplantation: A single-institute experience.
Umeda K; Okajima H; Kawaguchi K; Nodomi S; Saida S; Kato I; Hiramatsu H; Ogawa E; Yoshizawa A; Okamoto S; Uemoto S; Watanabe K; Adachi S
Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29341393
[TBL] [Abstract] [Full Text] [Related]
19. clinical characteristics of hepatocellular carcinoma patients with normal serum alpha-fetoprotein level: A study of 112 consecutive cases.
Li L; Chen J; Xu W; Ding X; Wang X; Liang J
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e336-e340. PubMed ID: 29071776
[TBL] [Abstract] [Full Text] [Related]
20. Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study.
Critelli R; Milosa F; Faillaci F; Condello R; Turola E; Marzi L; Lei B; Dituri F; Andreani S; Sighinolfi P; Manni P; Maiorana A; Caporali C; di Benedetto F; Del Buono M; De Maria N; Schepis F; Martinez-Chantar ML; Giannelli G; Villa E
Cell Death Dis; 2017 Aug; 8(8):e3017. PubMed ID: 28837142
[TBL] [Abstract] [Full Text] [Related]
[Next]
